Article Information
vol. 9 no. 1
Published By
Online ISSN
History
- Received September 13, 2022
- Accepted October 3, 2022
- Published online January 16, 2023.
Article Versions
- previous version (November 10, 2022 - 09:01).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©The authors 2023 This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
Author Information
- J. Gerry Coghlan1⇑,
- Sean Gaine2,
- Richard Channick3,
- Kelly M. Chin4,
- Camille du Roure5,
- J. Simon R. Gibbs6,
- Marius M. Hoeper7,
- Irene M. Lang8,
- Stephen C. Mathai9,
- Vallerie V. McLaughlin10,
- Lada Mitchell11,
- Gérald Simonneau12,
- Olivier Sitbon12,
- Victor F. Tapson13 and
- Nazzareno Galiè14
- 1Royal Free Hospital, London, UK
- 2Mater Misericordiae University Hospital, Dublin, Ireland
- 3David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
- 4UT Southwestern Medical Center, Dallas, TX, USA
- 5Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Global Medical Affairs, Allschwil, Switzerland
- 6National Heart and Lung Institute, Imperial College London, London, UK
- 7Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research, Hannover, Germany
- 8Division of Cardiology, Medical University of Vienna, Vienna, Austria
- 9Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 10University of Michigan, Ann Arbor, MI, USA
- 11Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Statistics & Decision Sciences - Medical Affairs and Established Products, Allschwil, Switzerland
- 12Hôpital Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
- 13Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 14Alma Mater Studiorum, University of Bologna and IRCCS-S.Orsola University Hospital, Bologna, Italy
- Corresponding author: J. Gerry Coghlan (gerry.coghlan{at}nhs.net)
Funding
Actelion Pharmaceuticals
Article usage
Altmetrics
Vol 9 Issue 1
Table of Contents
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
